



Influenza in the time of COVID-19: contributions from three years of the FluCov Project

Marco Del Riccio^{1,2}, Bronke Boudewijns¹, Susanne Heemskerk¹, Foekje Stelma¹, Daan van kooten¹, Caroline Schneeberger¹, Saverio Caini¹, Meral Akçay³, Erica Dueger³, John Paget^{1,†}

Affiliations: 1 Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands, 2 Department of Health Sciences, University of Florence, Italy, 3 Sanofi, Lyon, France, † In memoriam of dr. John Paget

Background

COVID-19 pandemic

Disruption in the global circulation of respiratory viruses

Evolution of influenza viruses' circulation after the pandemic?


Aim

Document and communicate the impacts of COVID-19 on influenza activity and preventive measures in 25 countries worldwide

Methods

Data sources

- WHO FluNet influenza epi-data
- OurWorldInData SARS-CoV-2 epi-data



- FluCov Bulletins
- FluCov Influenza Activity Reports

- National reports Vaccine coverage data
- Scientific literature evidence on B/Yamagata

Results


Reports and tools:

- 45 Bulletins + 23 Activity reports published between June 2021 and August 2024
- Interactive public dashboard for user-friendly data access and analysis developed

Research outputs:

- 6 manuscripts prepared, covering 4 topics:
- Impact of SARS-CoV-2 on National Influenza Centers (2023)
- Influenza vaccine coverage (2021 & in preparation)
- Influenza-susceptible populations (2023)

- Interactive FluCov dashboard
- Scientific publications and posters



FluCov Dashboard, Nivel website



Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment

Potential extinction of B/Yamagata lineage (2024 & in press)

Conclusion

The FluCov project continues to enrich our understanding of COVID-19's impact on influenza activity and preventive measures. Our ongoing research emphasizes the importance of continuous surveillance and communication to address respiratory viruses effectively. We encourage you to follow our results, as this project remains vital.

© 2024 Nivel, PO Box 1568, 3500 BN Utrecht, The Netherlands

The FluCov project was funded via an unrestricted grant by Sanofi to Nivel

of global surveillance databases

Saverio Caini PhD a 😤 🖾 , Adam Meijer PhD b, Prof Marta C Nunes PhD c d e, Laetitia Henaff BSc d, Malaika Zounon MD ^{c d}, Bronke Boudewijns MSc ^a, Marco Del Riccio MD ^{a f}, John Paget PhD ^{a †}

Caini et al., Lancet Microbe, 2024





Nivel FluCov Website

Sanofi Library of Congress

Contact: Marco Del Riccio - m.delriccio@nivel.nl

COI: MDR, BB, SH, and CS were funded via a research grant from Sanofi to Nivel (FluCov project). MA & ED are Sanofi employees and may hold company shares. All other authors declare no conflict of interest